勘误：病例报告：IV期肺腺癌中抗PD-1治疗诱导的PTEN突变。
Erratum: Case report: PTEN mutation induced by anti-PD-1 therapy in stage IV lung adenocarcinoma.
出版信息
Front Pharmacol. 2022 Oct 20;13:1058178. doi: 10.3389/fphar.2022.1058178. eCollection 2022.
Abstract
[This corrects the article DOI: 10.3389/fphar.2022.714408.].
摘要
[本文更正了文章的数字对象标识符：10.3389/fphar.2022.714408。]
相似文献
1
Erratum: Case report: PTEN mutation induced by anti-PD-1 therapy in stage IV lung adenocarcinoma.勘误：病例报告：IV期肺腺癌中抗PD-1治疗诱导的PTEN突变。
Front Pharmacol. 2022 Oct 20;13:1058178. doi: 10.3389/fphar.2022.1058178. eCollection 2022.
2
Case Report: PTEN Mutation Induced by anti-PD-1 Therapy in Stage IV Lung Adenocarcinoma.病例报告：IV期肺腺癌中抗PD-1治疗诱导的PTEN突变
Front Pharmacol. 2022 May 23;13:714408. doi: 10.3389/fphar.2022.714408. eCollection 2022.
3
The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare EGFR extracellular domain M277E mutation and high PD-L1 expression.阿法替尼和放疗对具有罕见 EGFR 外显子域 M277E 突变和高 PD-L1 表达的肺腺癌患者的影响。
J Cancer Res Ther. 2022 Apr;18(2):587-589. doi: 10.4103/jcrt.jcrt_348_22.
4
mRNA expression of programmed cell death ligand 1 and components of the phosphatidylinositol 3-kinase/AKT/phosphatase and tensin homolog pathway in epidermal growth factor receptor mutation-positive lung adenocarcinoma.程序性细胞死亡配体1的mRNA表达以及磷脂酰肌醇3激酶/蛋白激酶B/张力蛋白同源物通路各组分在表皮生长因子受体突变阳性肺腺癌中的表达
J Cancer Res Ther. 2019;15(4):914-920. doi: 10.4103/jcrt.JCRT_636_18.
5
Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.HER2 突变型肺腺癌中突变变异和共突变作为阿法替尼反应的基因组修饰物。
Oncologist. 2020 Mar;25(3):e545-e554. doi: 10.1634/theoncologist.2019-0547. Epub 2019 Nov 20.
6
Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.阿法替尼治疗 ERBB2 突变阳性晚期 NSCLC 患者的疗效：一项全球上市后研究结果。
J Thorac Oncol. 2018 Dec;13(12):1897-1905. doi: 10.1016/j.jtho.2018.07.093. Epub 2018 Aug 7.
7
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.比较阿法替尼与吉非替尼或厄洛替尼对携带非经典表皮生长因子受体突变的晚期肺腺癌患者的疗效。
Lung Cancer. 2017 Aug;110:56-62. doi: 10.1016/j.lungcan.2017.06.007. Epub 2017 Jun 13.
8
Afatinib for an EGFR exon 20 insertion mutation: A case report of progressive stage IV metastatic lung adenocarcinoma with 54 months' survival.阿法替尼用于表皮生长因子受体第20外显子插入突变：1例IV期转移性肺腺癌进展期患者生存54个月的病例报告
Asia Pac J Clin Oncol. 2018 Mar;14 Suppl 1:7-9. doi: 10.1111/ajco.12853.
9
Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.阿法替尼联合安罗替尼治疗新型 HER2 突变肺腺癌患者：病例报告及文献复习。
World J Surg Oncol. 2021 Nov 18;19(1):330. doi: 10.1186/s12957-021-02444-7.
10
EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.表皮生长因子受体（EGFR）第18外显子E709_T710缺失并插入D突变的IV期肺腺癌，对阿法替尼有反应。
Lung Cancer. 2017 Jun;108:45-47. doi: 10.1016/j.lungcan.2017.02.023. Epub 2017 Mar 1.
Zotero 插件